Verve Therapeutics, developing gene editing for heart disease, gets "Buy" rating despite losses.

Verve Therapeutics, a company developing gene editing treatments for cardiovascular diseases, has received a "Buy" consensus rating from six research firms, with an average price target of $25.50. Despite a recent quarter showing negative financial metrics, the company's lead product, VERVE-101, targets heart disease through gene editing. Analysts expect the company to post a loss per share of $2.49 for the current year.